Mcneil And Argus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.10 M
- Paid Up Capital ₹ 1.19 M
- Company Age 36 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.87 Cr
- Revenue Growth 70.93%
- Profit Growth 104.24%
- Ebitda 182.34%
- Net Worth 123.01%
- Total Assets 65.70%
About Mcneil And Argus Pharmaceuticals
Mcneil And Argus Pharmaceuticals Limited (MAAPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 10 March 1988 and has a history of 36 years and ten months. Its registered office is in Ambala, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.10 M and a paid-up capital of Rs 1.19 M.
The company currently has active open charges totaling ₹4.87 Cr.
Renu Chhibber, Pawan Chhibber, and Gurdev Chhibber serve as directors at the Company.
Company Details
-
Location
Ambala, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231HR1988PLC030217
-
Company No.
030217
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
10 Mar 1988
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Mcneil And Argus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gurdev Chhibber
|
Managing Director | 10-Mar-1988 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Renu Chhibber
|
Whole-Time Director | 11-Nov-1994 | Current |
|
Pawan Chhibber
|
Whole-Time Director | 18-Jul-2005 | Current |
Financial Performance of Mcneil And Argus Pharmaceuticals.
Mcneil And Argus Pharmaceuticals Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 70.93% increase. The company also saw a substantial improvement in profitability, with a 104.24% increase in profit. The company's net worth Soared by an impressive increase of 123.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mcneil And Argus Pharmaceuticals?
In 2020, Mcneil And Argus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹48.70 M
₹0
Charges Breakdown by Lending Institutions
- Others : 4.87 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Mar 2024 | Others | ₹4.87 Cr | Open |
How Many Employees Work at Mcneil And Argus Pharmaceuticals?
Unlock and access historical data on people associated with Mcneil And Argus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mcneil And Argus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mcneil And Argus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.